NASDAQ:MEIP - MEI Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.16 -0.18 (-7.69 %)
(As of 12/19/2018 08:00 AM ET)
Previous Close$2.34
Today's Range$2.15 - $2.38
52-Week Range$1.79 - $5.14
Volume426,100 shs
Average Volume259,942 shs
Market Capitalization$166.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.18
MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.

Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEIP
Previous SymbolNASDAQ:MSHL
CUSIPN/A
Phone858-369-7100

Debt

Debt-to-Equity RatioN/A
Current Ratio19.75
Quick Ratio19.76

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.62 million
Price / Sales94.84
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.72 per share
Price / Book3.00

Profitability

EPS (Most Recent Fiscal Year)($0.74)
Net Income$-40,060,000.00
Net Margins-2,508.05%
Return on Equity-71.32%
Return on Assets-41.07%

Miscellaneous

Employees32
Outstanding Shares71,130,000
Market Cap$166.43 million
OptionableOptionable

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma Inc (NASDAQ:MEIP) posted its quarterly earnings data on Thursday, November, 8th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The business earned $0.49 million during the quarter, compared to analyst estimates of $0.38 million. MEI Pharma had a negative return on equity of 71.32% and a negative net margin of 2,508.05%. View MEI Pharma's Earnings History.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for MEI Pharma.

What price target have analysts set for MEIP?

5 brokerages have issued 12-month target prices for MEI Pharma's stock. Their predictions range from $7.00 to $12.00. On average, they expect MEI Pharma's share price to reach $8.25 in the next year. This suggests a possible upside of 281.9% from the stock's current price. View Analyst Price Targets for MEI Pharma.

What is the consensus analysts' recommendation for MEI Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

Has MEI Pharma been receiving favorable news coverage?

Media stories about MEIP stock have trended neutral on Wednesday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. MEI Pharma earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the immediate future.

Who are some of MEI Pharma's key competitors?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:
  • Dr. Daniel P. Gold, CEO, Pres & Director (Age 64)
  • Mr. Brian G. Drazba CPA, Sec. & CFO (Age 57)
  • Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 54)
  • Dr. Robert D. Mass M.D., Chief Medical Officer (Age 64)
  • Mr. David A. Walsey, VP of IR & Corp. Communications

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vivo Capital LLC (8.12%), Vanguard Group Inc. (3.29%), Vanguard Group Inc (3.29%), Sio Capital Management LLC (3.24%), Renaissance Technologies LLC (3.14%) and Candriam Luxembourg S.C.A. (0.60%). Company insiders that own MEI Pharma stock include Charles V Baltic III and David M Urso. View Institutional Ownership Trends for MEI Pharma.

Which major investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, JPMorgan Chase & Co. and Opus Point Partners Management LLC. View Insider Buying and Selling for MEI Pharma.

Which major investors are buying MEI Pharma stock?

MEIP stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Candriam Luxembourg S.C.A., Bailard Inc., Macquarie Group Ltd., Sio Capital Management LLC, Monashee Investment Management LLC and Wasatch Advisors Inc.. View Insider Buying and Selling for MEI Pharma.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $2.16.

How big of a company is MEI Pharma?

MEI Pharma has a market capitalization of $166.43 million and generates $1.62 million in revenue each year. The company earns $-40,060,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is http://www.meipharma.com.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 3611 VALLEY CENTRE DRIVE SUITE 500, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]


MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  431
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel